<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-129392</identifier>
<setSpec>0001-6640</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Usefulness of the faecal calprotectin on the pediatric coeliac disease</dc:title>
<dc:description xml:lang="en">Introduction: The objective of the present research is to study the behavior of the faecal calprotectin in the pediatric coeliac disease, comparing its levels while receiving a diet with and without gluten. For the comparison, there were also included healthy children, and patients with diverse non-inflammatory digestive pathologies. Materials and methods: There have been collected stool samples from de novo coeliac patients (with gluten) and from follow-up coeliac patients (without gluten). As control groups, there were included healthy children without any digestive pathology and others with diverse digestive non-diagnosed disorders from the inflammatory bowel disease. Results: The faecal calprotectin was significantly higher in the coeliac patients with gluten (119.2 ± 122.6 µg/g) than in the patients with the gluten-free diet (21.5 ± 24.7 µg/g). The later showed similar values to those in the healthy control group. Conclusions: The faecal calprotectin is higher in the coeliac patients with gluten ingestion than in the coeliac patients with the gluten-free diet and in the healthy group. This could be used as a marker for early detection of gluten ingestion (AU)</dc:description>
<dc:creator>Clemente Yago, F</dc:creator>
<dc:creator>Clemetne Bellido, F</dc:creator>
<dc:creator>Pérez Lledó, E</dc:creator>
<dc:creator>Manrique Moral, O</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: El objetivo del presente estudio es analizar el comportamiento de la calprotectina fecal en los pacientes pediátricos con enfermedad celiaca, comparando sus niveles mientras recibían dieta con y sin gluten. También se han incluido en la comparación pacientes sanos y con diversas patologías digestivas no inflamatorias. Material y métodos: Se han recogido muestras de heces de pacientes celiacos con diagnóstico de novo (con gluten) y pacientes en seguimiento (sin gluten). Se incluyeron en el grupo control niños sanos sin patología digestiva y otros con diversos trastornos digestivos no diagnosticados de enfermedad inflamatoria intestinal. Resultados: La calprotectina fecal fue significativamente más alta en los pacientes celiacos que recibieron una dieta con gluten (119,2 ± 122,6 µg/g) que en los que recibieron una dieta sin gluten (21,5 ± 24,7 µg/g). Estos últimos presentaron valores similares al grupo control sano. Conclusiones: La calprotectina fecal está elevada en los pacientes celiacos con ingesta de gluten respecto a los celiacos con dieta sin gluten y los pacientes sanos. Este marcador podría usarse para la detección precoz de la ingesta de gluten (AU)</dc:description>
<dc:source>Acta Pediatr Esp;72(9): 182-186, oct. 2014. tab, graf</dc:source>
<dc:identifier>ibc-129392</dc:identifier>
<dc:title xml:lang="es">Utilidad de la calprotectina fecal en la enfermedad celiaca pediátrica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d5346^s29165</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d2396^s22002</dc:subject>
<dc:subject>^d2154^s22002</dc:subject>
<dc:subject>^d7426^s22032</dc:subject>
<dc:subject>^d2481^s22032</dc:subject>
<dc:subject>^d32175^s22002</dc:subject>
<dc:type>article</dc:type>
<dc:date>201410</dc:date>
</metadata>
</record>
</ibecs-document>
